Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Haploidentical Allogeneic Transplant w/Post Transplant Infusion of Regulatory T-cells (BMT Protocol 204)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2012 by Stanford University.
Recruitment status was:  Active, not recruiting
Doris Duke Charitable Foundation
Information provided by (Responsible Party):
Ginna Laport, Stanford University Identifier:
First received: January 11, 2010
Last updated: September 13, 2012
Last verified: September 2012
When a match related or matched unrelated donor is not available a Haploidentical donor (parent, sibling or child)is immediately available. The challenges associated with haploidentical HCT include increased risk of GVHD, graft rejection and impaired immune reconstitution. This trial will evaluate the safety and feasibility of simultaneous administration of conventional T cells and regulatory T cells after haploidentical allogeneic hematopoietic cell transplantation to overcome these challenges.

Condition Intervention
Leukemia Chronic Myelogenous Leukemia (CML)
Blood and Marrow Transplant (BMT)
Myelodysplastic Syndromes (MDS)
Lymphomas: Non-Hodgkin
Device: ClinMACS
Drug: Stem Cells

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Feasibility Trial of Post Transplant Infusion of Allogeneic Regulatory T Cells Simultaneously With Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical Related Donors

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Determine safety and feasibility of infusing conventional T cells and regulatory T cell after HCT. [ Time Frame: 1 year ]
  • Determine maximum tolerated dose of infused regulatory and conventional T cells [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Determine 1 year OS and EFS, incidence and severity of GVHD; incidence of serious infections, immune reconstitution [ Time Frame: 1 year ]

Estimated Enrollment: 24
Study Start Date: June 2009
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Post Transplant Infusion arm Device: ClinMACS Drug: Stem Cells


Ages Eligible for Study:   up to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:Recipient Inclusion Criteria

3.1.1 Patients with the following diseases that are histopathologically confirmed are eligible:

  1. Acute leukemia (in first remission with poor risk factors and molecular prognosis; AML with -5,-7, t(6;9), tri8, -11 and ALL with Ph+ t(9;22), t(4;22), (q34;q11)
  2. Acute leukemia with refractory disease or >CR1
  3. Chronic myelogenous leukemia (accelerated, blast or second chronic phase)
  4. Myelodysplastic syndrome (in high and high intermediate risk categories)
  5. Non-Hodgkin's lymphoma with poor risk features not suitable for autologous transplantation
  6. Refractory CLL

3.1.2 There are no limits on amount of prior therapy but there must be at least 21 days from the end of most recent prior therapy to start of transplant conditioning regimen.

3.1.3 The recipient must be <= 60 years old at time of registration.

3.1.5 Karnofsky Performance Status > 70%

3.1.6 The recipient must have a related donor genotypically HLA-A, B,C and DRB1, DQ loci haploidentical to the recipient (but differing for 2-3 HLA alleles on the unshared haplotype in the GvHD direction) and no HLA matched sibling or matched unrelated donor is identified.

3.1.7 Adequate cardiac and pulmonary function (LVEF > 45%, DLCO >50% corrected for hemoglobin)

3.1.8 Serum creatinine <1.5 mg/dL or creatinine clearance >50 ml/min for those above serum creatinine of 1.5; serum bilirubin <2.0 mg/dL; ALT <2x ULN (unless secondary to disease)

3.1.9 No prior myeloablative therapy or hematopoeitic cell transplantation

Donor Inclusion Criteria

3.3.1 Age < 70 years and weight > 25 kg. 3.3.2 Medical history and physical examination confirm good health status as defined by institutional standards 3.3.3 Seronegative for HIV Ag, hepatitis B sAg or PCR+ or hepatitis C ab or PCR+ within 30 days of apheresis collection 3.3.4 Genotypically haploidentical as determined by HLA typing 3.3.5 Female donors of child-bearing potential must have a negative serum or urine beta-HCG test within three weeks of mobilization 3.3.6 Capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central catheter should leukapheresis via peripheral vein be inadequate 3.3.7 Capable of agreeing to second donation of PBPC (or a bone marrow harvest) should the patient fail to demonstrate sustained engraftment following the transplant 3.3.8 The donor or legal guardian greater than 18 years of age, capable of signing an IRB-approved consent form.

3.3.9 Donor Selection

The order of donor section will be as follows:

  1. If available, the recipient's biological mother will be the preferential donor
  2. If the biological mother is not available, then other available haploidentical donors will be selected based upon the presence of NK alloreactivity between donor and recipient. The donor will be selected based on the presence of NK alloreactivity as determined by high-resolution HLA typing of the C locus of both donor and recipient. Recipients lacking a KIR-ligand present in the donor along with the corresponding KIR defines "NK alloreactivity". An NK alloreactive donor will be preferentially chosen.
  3. If more than 1 NK alloreactive donor is available, then preference will be to use an NK alloreactive donor that is CMV seronegative.

Exclusion Criteria:Recipient Exclusion Criteria

3.2.1 The recipient is a suitable candidate for autologous transplantation or allogeneic transplantation with an available matched related or unrelated donor.

3.2.2 Seropositive for any of the following: HIV ab, hepatitis B sAg or PCR+ or hepatitis C ab or PCR+ 3.2.3 History of invasive Aspergillosis; presence of any other active, uncontrolled bacterial, viral or fungal infection 3.2.4 Uncontrolled CNS disease involvement 3.2.7 The recipient is a lactating female

3.4 Donor Exclusion Criteria 3.4.1 Evidence of active infection or viral hepatitis 3.4.3 Factors which place the donor at increased risk for complications from leukapheresis or G-CSF therapy 3.4.4 Lactating female 3.4.5 HIV positive

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01050764

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Ginna Laport
Doris Duke Charitable Foundation
Principal Investigator: Ginna Laport Stanford University
  More Information

Responsible Party: Ginna Laport, Associate Professor of Medicine (Blood and Marrow Transplantation), Stanford University Identifier: NCT01050764     History of Changes
Other Study ID Numbers: BMT204
SU-03312009-2059 ( Other Identifier: Stanford University )
15919 ( Other Identifier: Stanford IRB )
Study First Received: January 11, 2010
Last Updated: September 13, 2012

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Myeloproliferative Disorders processed this record on April 25, 2017